Cardiosphere-derived cells and ischemic heart failure

Cardiology in Review

Volumn 26, Issue 1, 2018, Pages 8-21

  Ashur, Carmel ^a   Frishman, William H ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

Cardiosphere derived cells; Ischemic heart failure; Myocardial infarction; Stem cells

Indexed keywords

CARDIAC STEM CELL; CELL GROWTH; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL REGENERATION; CELL THERAPY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; PHENOTYPE; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL RATE; ALLOTRANSPLANTATION; ANIMAL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CYTOLOGY; PROCEDURES; TRANSPLANTATION;

ANIMALS; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; MYOCYTES, CARDIAC; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 85038396626     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000173     Document Type: Review

References (145)

1. Benjamin, EJ, Michael JB, Stephanie EC, et al. Heart Disease and Stroke Statistics-2017 Update: a report from the American Hearta Association. Circulation. 2017; 135:e146-603.
2. Heidenreich PA, Trogdon JG, Khavjou OA, et al.; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011; 123:933-944.
3. Moscucci M, Eagle KA. Door-to-balloon time in primary percutaneous coronary intervention: is the 90-minute gold standard an unreachable chimera? Circulation. 2006; 113:1048-1050.
4. Samer JS, Young-Xu Y, Graboys TB, et al. Long-term outcomes of optimized medical management of outpatients with stable coronary artery disease. Am J Cardiol 2004; 93:294-299.
5. Birati E Y, Rame JE. Post-heart transplant complications. Crit Care Clin. 2014; 30:629-637.
6. Holley CT, Harvey L, John R. Left ventricular assist devices as a bridge to cardiac transplantation. J Thorac Dis. 2014; 6:1110-1119.
7. Yi BA, Mummery CL, Chien KR. Direct cardiomyocyte reprogramming: a new direction for cardiovascular regenerative medicine. Cold Spring Harb Perspect Med. 2013; 3:a014050.
8. Muraoka N, Ieda M. Direct reprogramming of fibroblasts into myocytes to reverse fibrosis. Annu Rev Physiol. 2014; 76:21-37.
9. Murry CE, Pu WT. Reprogramming fibroblasts into cardiomyocytes. N Engl J Med. 2011; 364:177-178.
10. Smith RR, Barile L, Cho HC, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation. 2007; 115:896-908.
11. Machida M, Takagaki Y, Matsuoka R, et al. Proteomic comparison of spherical aggregates and adherent cells of cardiac stem cells. Int J Cardiol. 2011; 153:296-305.
12. Messina E, De Angelis L, Frati G, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004; 95:911-921.
13. Sun Y, Chi D, Tan M, et al. Cadaveric cardiosphere-derived cells can maintain regenerative capacity and improve the heart function of cardiomyopathy. Cell Cycle. 2016; 15:1248-1256.
14. Hensley MT, de Andrade J, Keene B, et al. Cardiac regenerative potential of cardiosphere-derived cells from adult dog hearts. J Cell Mol Med. 2015; 19:1805-1813.
15. Suzuki G, Weil BR, Leiker MM, et al. Global intracoronary infusion of allogeneic cardiosphere-derived cells improves ventricular function and stimulates endogenous myocyte regeneration throughout the heart in swine with hibernating myocardium. PLoS One. 2014; 9:e113009.
16. Li TS, Cheng K, Malliaras K, et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol. 2012; 59:942-953.
17. Davis DR, Ruckdeschel Smith R, Marbán E. Human cardiospheres are a source of stem cells with cardiomyogenic potential. Stem Cells. 2010; 28:903-904.
18. White AJ, Smith RR, Matsushita S, et al. Intrinsic cardiac origin of human cardiosphere-derived cells. Eur Heart J. 2013; 34:68-75.
19. Cheng K, Ibrahim A, Hensley MT, et al. Relative roles of CD90 and c-kit to the regenerative efficacy of cardiosphere-derived cells in humans and in a mouse model of myocardial infarction. J Am Heart Assoc. 2014; 3:e001260.
20. Mishra R, Vijayan K, Colletti EJ, et al. Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation. 2011; 123:364-373.
21. Simpson DL, Mishra R, Sharma S, et al. A strong regenerative ability of cardiac stem cells derived from neonatal hearts. Circulation. 2012; 126(11 suppl 1):S46-S53.
22. Gallet R, Tseliou E, Dawkins J, et al. Intracoronary delivery of self-assembling heart-derived microtissues (cardiospheres) for prevention of adverse remodeling in a pig model of convalescent myocardial infarction. Circ Cardiovasc Interv. 2015; 8:e002391.
23. Johnston P V, Sasano T, Mills K, et al. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation. 2009; 120:1075-1083, 7 p following 1083.
24. Tseliou E, Kanazawa H, Dawkins J, et al. Widespread myocardial delivery of heart-derived stem cells by nonocclusive triple-vessel intracoronary infusion in porcine ischemic cardiomyopathy: superior attenuation of adverse remodeling documented by magnetic resonance imaging and histology. PLoS One. 2016; 11:e0144523.
25. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012; 379:895-904.
26. Dilated cardiomYopathy iNtervention With Allogeneic Myocard Ially-regenerative Cells (DYNAMIC) - Full Text View - ClinicalTrials.gov [Internet]. [cited 19 Dec 2016]. Available at: https://clinicaltrials.gov/ct2/show/NCT02293603?term=NCT02293603&rank=1. Accessed May 25, 2017.
27. Shah VK, Shalia KK. Stem cell therapy for acute myocardial infarction-long term 24 months follow-up. J Clin Trials Cardiol. 2014; 1: 1-5.
28. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012; 308:2369-2379.
29. Williams AR, Trachtenberg B, Velazquez DL, et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res. 2011; 108:792-796.
30. Chugh AR, Beache GM, Loughran JH, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation. 2012; 126(11 suppl 1):S54-S64.
31. Chimenti I, Smith RR, Li TS, et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res. 2010; 106:971-980.
32. Suzuki G, Young RF, Leiker MM, et al. Heart-derived stem cells in miniature swine with coronary microembolization: novel ischemic cardiomy-opathy model to assess the efficacy of cell-based therapy. Stem Cells Int. 2016; 2016:6940195.
33. Lee ST, White AJ, Matsushita S, et al. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol. 2011; 57:455-465.
34. Quevedo HC, Hatzistergos KE, Oskouei BN, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A. 2009; 106:14022-14027.
35. Blázquez R, Sánchez-Margallo FM, Crisóstomo V, et al. Intrapericardial delivery of cardiosphere-derived cells: an immunological study in a clinically relevant large animal model. PLoS One. 2016; 11:e0149001.
36. Cheng K, Li TS, Malliaras K, et al. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circ Res. 2010; 106:1570-1581.
37. Kwon Y W, Yang HM, Cho HJ. Cell therapy for myocardial infarction. Int J Stem Cells. 2010; 3:8-15.
38. Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013; 113:810-834.
39. Freyman T, Polin G, Osman H, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J. 2006; 27:1114-1122.
40. Wollert KC, Drexler H. Clinical applications of stem cells for the heart. Circ Res. 2005; 96:151-163.
41. Cheng K, Blusztajn A, Shen D, et al. Functional performance of human cardiosphere-derived cells delivered in an in situ polymerizable hyaluronangelatin hydrogel. Biomaterials. 2012; 33:5317-5324.
42. Masumoto H, Matsuo T, Yamamizu K, et al. Pluripotent stem cell-engineered cell sheets reassembled with defined cardiovascular populations ameliorate reduction in infarct heart function through cardiomyocyte-mediated neovascularization. Stem Cells. 2012; 30:1196-1205.
43. Saito S, Miyagawa S, Sakaguchi T, et al. Myoblast sheet can prevent the impairment of cardiac diastolic function and late remodeling after left ventricular restoration in ischemic cardiomyopathy. Transplantation. 2012; 93:1108-1115.
44. Suzuki R, Hattori F, Itabashi Y, et al. Omentopexy enhances graft function in myocardial cell sheet transplantation. Biochem Biophys Res Commun. 2009; 387:353-359.
45. Sawa Y, Miyagawa S, Sakaguchi T, et al. Tissue engineered myoblast sheets improved cardiac function sufficiently to discontinue LVAS in a patient with DCM: report of a case. Surg Today. 2012; 42:181-184.
46. Hosoyama T, Samura M, Kudo T, et al. Cardiosphere-derived cell sheet primed with hypoxia improves left ventricular function of chronically infarcted heart. Am J Transl Res. 2015; 7:2738-2751.
47. Takehara N, Tsutsumi Y, Tateishi K, et al. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol. 2008; 52:1858-1865.
48. Aghila Rani KG, Kartha CC. Effects of epidermal growth factor on proliferation and migration of cardiosphere-derived cells expanded from adult human heart. Growth Factors. 2010; 28:157-165.
49. Chimenti I, Pagano F, Cavarretta E, et al. B-blockers treatment of cardiac surgery patients enhances isolation and improves phenotype of cardiosphere-derived cells. Sci Rep. 2016; 6:36774.
50. Kapelios CJ, Nanas JN, Malliaras K. Allogeneic cardiosphere-derived cells for myocardial regeneration: current progress and recent results. Future Cardiol. 2016; 12:87-100.
51. From AM, Maleszewski JJ, Rihal CS. Current status of endomyocardial biopsy. Mayo Clin Proc. 2011; 86:1095-1102.
52. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008; 8:726-736.
53. Malliaras K, Li TS, Luthringer D, et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation. 2012; 125:100-112.
54. Beltrami A P, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003; 114:763-776.
55. Lauden L, Boukouaci W, Borlado LR, et al. Allogenicity of human cardiac stem/progenitor cells orchestrated by programmed death ligand 1. Circ Res. 2013; 112:451-464.
56. Weil BR, Suzuki G, Leiker MM, et al. Comparative efficacy of intracoronary allogeneic mesenchymal stem cells and cardiosphere-derived cells in swine with hibernating myocardium. Circ Res. 2015; 117:634-644.
57. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014; 32:252-260.
58. Malliaras K, Smith RR, Kanazawa H, et al. Validation of contrast-enhanced magnetic resonance imaging to monitor regenerative efficacy after cell therapy in a porcine model of convalescent myocardial infarction. Circulation. 2013; 128:2764-2775.
59. Tseliou E, Pollan S, Malliaras K, et al. Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched rat strains. J Am Coll Cardiol. 2013; 61:1108-1119.
60. Kanazawa H, Tseliou E, Malliaras K, et al. Cellular postconditioning: allogeneic cardiosphere-derived cells reduce infarct size and attenuate microvascular obstruction when administered after reperfusion in pigs with acute myocardial infarction. Circ Heart Fail. 2015; 8:322-332.
61. Yee K, Malliaras K, Kanazawa H, et al. Allogeneic cardiospheres delivered via percutaneous transendocardial injection increase viable myocardium, decrease scar size, and attenuate cardiac dilatation in porcine ischemic cardiomyopathy. PLoS One. 2014; 9:e113805.
62. Crisostomo V, Baez-Diaz C, Maestre J, et al. Delayed administration of allogeneic cardiac stem cell therapy for acute myocardial infarction could ameliorate adverse remodeling: experimental study in swine. J Transl Med. 2015; 13:156.
63. Cheng K, Malliaras K, Smith RR, et al. Human cardiosphere-derived cells from advanced heart failure patients exhibit augmented functional potency in myocardial repair. JACC Heart Fail. 2014; 2:49-61.
64. Huang C, Gu H, Yu Q, et al. Sca-1+ cardiac stem cells mediate acute cardioprotection via paracrine factor SDF-1 following myocardial ischemia/reperfusion. PLoS One. 2011; 6:e29246.
65. Heeschen C, Lehmann R, Honold J, et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation. 2004; 109:1615-1622.
66. Barile L, Lionetti V, Cervio E, et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res. 2014; 103:530-541.
67. Ibrahim AG, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports. 2014; 2:606-619.
68. Barile L, Gherghiceanu M, Popescu LM, et al. Ultrastructural evidence of exosome secretion by progenitor cells in adult mouse myocardium and adult human cardiospheres. J Biomed Biotechnol. 2012; 2012:354605.
69. Vacanti V, Kong E, Suzuki G, et al. Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J Cell Physiol. 2005; 205:194-201.
70. Lee AY, Lee J, Kim CL, et al. Comparative studies on proliferation, molecular markers and differentiation potential of mesenchymal stem cells from various tissues (adipose, bone marrow, ear skin, abdominal skin, and lung) and maintenance of multipotency during serial passages in miniature pig. Res Vet Sci. 2015; 100:115-124.
71. Purandare B, Teklemariam T, Zhao L, et al. Temporal HLA profiling and immunomodulatory effects of human adult bone marrow- and adipose-derived mesenchymal stem cells. Regen Med. 2014; 9:67-79.
72. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361:13-20.
73. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990; 81:1161-1172.
74. St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994; 89:68-75.
75. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996; 93:223-228.
76. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998; 97:765-772.
77. Kloner RA Current state of clinical translation of cardioprotective agents for acute myocardial infarction. Circ Res. 2013; 113:451-463.
78. Kin H, Zhao ZQ, Sun HY, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res. 2004; 62:74-85.
79. Yang XM, Proctor JB, Cui L, et al. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol. 2004; 44:1103-1110.
80. Carr CA, Stuckey DJ, Tan JJ, et al. Cardiosphere-derived cells improve function in the infarcted rat heart for at least 16 weeks-an MRI study. PLoS One. 2011; 6:e25669.
81. Malliaras K, Zhang Y, Seinfeld J, et al. Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heart. EMBO Mol Med. 2013; 5:191-209.
82. Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014; 63:110-122.
83. Malliaras K, Marbán E. Cardiac regeneration validated. Nat Biotechnol. 2015; 33:587.
84. Malliaras K, Kreke M, Marbán E. The stuttering progress of cell therapy for heart disease. Clin Pharmacol Ther. 2011; 90:532-541.
85. Isogai T, Yasunaga H, Matsui H, et al. Hospital volume and cardiac complications of endomyocardial biopsy: a retrospective cohort study of 9508 adult patients using a nationwide inpatient database in Japan. Clin Cardiol. 2015; 38:164-170.
86. Ishigami S, Ohtsuki S, Tarui S, et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res. 2015; 116:653-664.
87. Tarui S, Ishigami S, Ousaka D, et al. Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial. J Thorac Cardiovasc Surg. 2015; 150:1198-1207, 1208.e1.
88. Chakravarty T, Makkar RR, Ascheim DD, et al. ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: rationale and design. Cell Transplant. 2017; 26:205-214.
89. Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res. 2008; 102:1319-1330.
90. Malliaras K, Marbán E. Moving beyond surrogate endpoints in cell therapy trials for heart disease. Stem Cells Transl Med. 2014; 3:2-6.
91. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrowderived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006; 367:113-121.
92. Schächinger V, Erbs S, Elsässer A, et al.; REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006; 355:1210-1221.
93. Tendera M, Wojakowski W, Ruzyłło W, et al; REGENT Investigators. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J. 2009; 30:1313-1321.
94. Meyer G P, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006; 113:1287-1294.
95. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009; 324:98-102.
96. Soonpaa MH, Field LJ. Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts. Am J Physiol. 1997; 272(1 Pt 2):H220-H226.
97. Kajstura J, Gurusamy N, Ogórek B, et al. Myocyte turnover in the aging human heart. Circ Res. 2010; 107:1374-1386.
98. Hsieh PC, Segers VF, Davis ME, et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med. 2007; 13:970-974.
99. Loffredo FS, Steinhauser ML, Gannon J, et al. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell. 2011; 8:389-398.
100. Tang XL, Rokosh G, Sanganalmath SK, et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation. 2010; 121:293-305.
101. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010; 107:913-922.
102. Malliaras K, Ibrahim A, Tseliou E, et al. Stimulation of endogenous cardioblasts by exogenous cell therapy after myocardial infarction. EMBO Mol Med. 2014; 6:760-777.
103. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol. 2006; 36:2566-2573.
104. Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007; 262:509-525.
105. Cho HJ, Lee N, Lee JY, et al. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J Exp Med. 2007; 204:3257-3269.
106. Eschenhagen T, Bolli R, Braun T, et al: Cardiomyocyte regeneration: a consensus statement. Circulation 2017; 136:680-686.
107. Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 2001; 104:1046-1052.
108. Gnecchi M, He H, Liang OD, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005; 11:367-368.
109. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006; 20:661-669.
110. Gnecchi M, Zhang Z, Ni A, et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008; 103:1204-1219.
111. Rodrigo SF, van Ramshorst J, Hoogslag GE, et al. Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up. J Cardiovasc Transl Res. 2013; 6:816-825.
112. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebocontrolled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009; 54:2277-2286.
113. Chen L, Wang Y, Pan Y, et al. Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/reperfusion injury. Biochem Biophys Res Commun. 2013; 431:566-571.
114. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-tran-scriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008; 9:102-114.
115. Wienholds E, Kloosterman W P, Miska E, et al. MicroRNA expression in zebrafish embryonic development. Science. 2005; 309:310-311.
116. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014; 42:D68-D73.
117. Riffo-Campos AL, Riquelme I, Brebi-Mieville P. Tools for sequence-based miRNA target prediction: what to choose? Intl J Molec Sci. 2016; 17:1987.
118. Das S, Halushka MK. Extracellular vesicle microRNA transfer in cardiovascular disease. Cardiovasc Pathol. 2015; 24:199-206.
119. Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest. 2014; 124:2136-2146.
120. Feng Y, Huang W, Wani M, et al. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22. PLoS One. 2014; 9:e88685.
121. Wang X, Zhu H, Zhang X, et al. Loss of the miR-144/451 cluster impairs ischaemic preconditioning-mediated cardioprotection by targeting Rac-1. Cardiovasc Res. 2012; 94:379-390.
122. Halkein J, Tabruyn S P, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013; 123:2143-2154.
123. Yu B, Gong M, Wang Y, et al. Cardiomyocyte protection by GATA-4 gene engineered mesenchymal stem cells is partially mediated by translocation of miR-221 in microvesicles. PLoS One. 2013; 8:e73304.
124. Perez-Ilzarbe M, Agbulut O, Pelacho B, et al. Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. Eur J Heart Fail. 2008; 10:1065-1072.
125. Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004; 428:664-668.
126. Maguire G. Stem cell therapy without the cells. Commun Integr Biol. 2013; 6:e26631.
127. Suzuki E, Fujita D, Takahashi M, et al. Stem cell-derived exosomes as a therapeutic tool for cardiovascular disease. World J Stem Cells. 2016; 8:297-305.
128. Sharma S, Mishra R, Simpson D, et al. Cardiosphere-derived cells from pediatric end-stage heart failure patients have enhanced functional activity due to the heat shock response regulating the secretome. Stem Cells. 2015; 33:1213-1229.
129. Xu Y, Luo F, Liu Y, et al. Exosomal miR-21 derived from arsenite-transformed human bronchial epithelial cells promotes cell proliferation associated with arsenite carcinogenesis. Arch Toxicol. 2015; 89:1071-1082.
130. Schenke-Layland K, Strem BM, Jordan MC, et al. Adipose tissue-derived cells improve cardiac function following myocardial infarction. J Surg Res. 2009; 153:217-223.
131. Singla DK Stem cells in the infarcted heart. J Cardiovasc Transl Res. 2010; 3:73-78.
132. Wang Y, Zhang L, Li Y, et al. Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium. Int J Cardiol. 2015; 192:61-69.
133. Maguire G, Friedman P. The systems biology of stem cell released molecules - based therapeutics. Int Sch Res Notices. 2013; 2013:784541.
134. Shibuya M, Miura T, Fukagawa Y, et al. Tongue muscle-derived stem cells express connexin 43 and improve cardiac remodeling and survival after myocardial infarction in mice. Circ J. 2010; 74:1219-1226.
135. Mureli S, Gans C P, Bare DJ, et al. Mesenchymal stem cells improve cardiac conduction by upregulation of connexin 43 through paracrine signaling. Am J Physiol Heart Circ Physiol. 2013; 304:H600-H609.
136. Kathju S, Gallo PH, Satish L. Scarless integumentary wound healing in the mammalian fetus: molecular basis and therapeutic implications. Birth Defects Res C Embryo Today. 2012; 96:223-236.
137. Lorenz H P, Longaker MT, Perkocha LA, et al. Scarless wound repair: a human fetal skin model. Development. 1992; 114:253-259.
138. Ohnishi S, Sumiyoshi H, Kitamura S, et al. Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Lett. 2007; 581:3961-3966.
139. Xu X, Xu Z, Xu Y, et al. Effects of mesenchymal stem cell transplantation on extracellular matrix after myocardial infarction in rats. Coron Artery Dis. 2005; 16:245-255.
140. Matar AA, Chong JJ. Stem cell therapy for cardiac dysfunction. Springerplus. 2014; 3:440.
141. Deckers J W, Hare JM, Baughman KL. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. J Am Coll Cardiol. 1992; 19:43-47.
142. Milasinovic D, Mohl W. Contemporary perspective on endogenous myocardial regeneration. World J Stem Cells. 2015; 7:793-805.
143. Dasa SSK, Suzuki R, Mugler E, et al. Evaluation of pharmacokinetic and pharmacodynamic profiles of liposomes for the cell type-specific delivery of small molecule drugs. Nanomed. 2017. doi:10.1016/j.nano.2017.07.005.
144. McGuire MJ, Samli KN, Johnston SA, et al. In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo. J Mol Biol. 2004; 342:171-182.
145. Kanki S, Jaalouk DE, Lee S, et al. Identification of targeting peptides for ischemic myocardium by in vivo phage display. J Mol Cell Cardiol. 2011; 50:841-848.